Literature DB >> 14974078

Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7).

Gerbert A Jansen1, Hans R Waterham, Ronald J A Wanders.   

Abstract

Refsum disease has long been known to be an inherited disorder of lipid metabolism characterized by the accumulation of phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) caused by an alpha-oxidation deficiency of this branched chain fatty acid in peroxisomes. The mechanism of phytanic acid alpha-oxidation and the enzymes involved had long remained mysterious, but they have been resolved in recent years. This has led to the resolution of the molecular basis of Refsum disease. Interestingly, Refsum disease is genetically heterogeneous; two genes, PHYH (also named PAHX) and PEX7, have been identified to cause Refsum disease, as reviewed in this work. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14974078     DOI: 10.1002/humu.10315

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  21 in total

Review 1.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 2.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

3.  Effects of Low Phytanic Acid-Concentrated DHA on Activated Microglial Cells: Comparison with a Standard Phytanic Acid-Concentrated DHA.

Authors:  María Belén Ruiz-Roso; Elena Olivares-Álvaro; José Carlos Quintela; Sandra Ballesteros; Juan F Espinosa-Parrilla; Baltasar Ruiz-Roso; Vicente Lahera; Natalia de Las Heras; Beatriz Martín-Fernández
Journal:  Neuromolecular Med       Date:  2018-05-30       Impact factor: 3.843

Review 4.  [Adult Refsum disease. A retinal dystrophy with therapeutic options].

Authors:  K Rüther
Journal:  Ophthalmologe       Date:  2005-08       Impact factor: 1.059

Review 5.  Current concepts in the treatment of hereditary ataxias.

Authors:  Pedro Braga Neto; José Luiz Pedroso; Sheng-Han Kuo; C França Marcondes Junior; Hélio Afonso Ghizoni Teive; Orlando Graziani Povoas Barsottini
Journal:  Arq Neuropsiquiatr       Date:  2016-03       Impact factor: 1.420

6.  Next-generation sequencing-based molecular diagnosis of 82 retinitis pigmentosa probands from Northern Ireland.

Authors:  Li Zhao; Feng Wang; Hui Wang; Yumei Li; Sharon Alexander; Keqing Wang; Colin E Willoughby; Jacques E Zaneveld; Lichun Jiang; Zachry T Soens; Philip Earle; David Simpson; Giuliana Silvestri; Rui Chen
Journal:  Hum Genet       Date:  2014-12-04       Impact factor: 4.132

Review 7.  [Genetics of neuropathies].

Authors:  B Gess; A Schirmacher; P Young
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

8.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Non-manifesting Refsum heterozygotes carrying the c.135-2A>G PAHX gene transition.

Authors:  Josef Finsterer; Günther Regelsberger; Till Voigtländer
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

10.  Ataxia with loss of Purkinje cells in a mouse model for Refsum disease.

Authors:  Sacha Ferdinandusse; Anna W M Zomer; Jasper C Komen; Christina E van den Brink; Melissa Thanos; Frank P T Hamers; Ronald J A Wanders; Paul T van der Saag; Bwee Tien Poll-The; Pedro Brites
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.